ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Pharmacologic treatment and prevention of high-altitude illness (HAI)

Pharmacologic treatment and prevention of high-altitude illness (HAI)
Condition Preferred agent Alternatives
AMS/HACE Prevention*

Acetazolamide

Adults: 125 mg orally every 12 hours

Children: 2.5 mg/kg (maximum single dose: 125 mg) orally every 12 hours

Duration: Start day before ascent and continue 2 to 3 days at maximum altitude; may use once at night thereafter to improve sleep

Dexamethasone

Adults: 2 mg orally every 6 hours or 4 mg orally every 12 hours

Children: Acetazolamide preferred; do not use for prophylaxis

Duration: Start day of ascent and continue 2 to 3 days at maximum altitude but for no more than 7 days total
Treatment of mild AMSΔ

Acetazolamide

Adults: 125 to 250 mg orally every 12 hours

Children: 2.5 mg/kg (maximum single dose: 250 mg) orally every 12 hours

Duration: Continue for 24 hours after symptoms resolve or descent completed

Dexamethasone

Adults: 2 to 4 mg orally every 6 hours

Children: 0.15 mg/kg (maximum single dose: 4 mg) orally every 6 hours

Duration: Continue until 24 hours after symptoms resolve or descent completed but for no more than 7 days total
Treatment of moderate to severe AMS

Dexamethasone

Adults: 4 mg orally every 6 hours

Children: 0.15 mg/kg (maximum single dose: 4 mg) orally every 6 hours

Duration: Continue for 24 hours after symptoms resolve or descent completed but for no more than 7 days total

Acetazolamide

Adults: 125 to 250 mg orally every 12 hours

Children: 2.5 mg/kg (maximum single dose: 250 mg) orally every 12 hours

Duration: Continue for 24 hours after symptoms resolve or descent completed
Treatment of HACE

Dexamethasone

Adults: 8 to 10 mg orally/IM/IV once, then 4 mg orally/IM/IV every 6 hours

Children: 0.15 mg/kg (maximum single dose: 4 mg) every 6 hours

Duration: Continue until 24 hours after symptoms resolve or descent completed but for no more than 7 days total

Acetazolamide

Adults: 250 mg orally every 12 hours; may use as adjunct with dexamethasone; not for monotherapy

Children: 2.5 mg/kg (maximum single dose: 250 mg) orally every 12 hours

Duration: Continue until 24 hours after symptoms resolve or descent completed
HAPE Prevention*

Nifedipine

Adults and children ≥50 kg: 30 mg extended-release orally every 12 hours

Duration: Start day before ascent and continue for 5 days at maximum altitude

Acetazolamide

Pediatric re-entry HAPE prevention only (<50 kg): 2.5 mg/kg (maximum single dose: 125 mg) orally every 12 hours

Duration: Start day before ascent and continue 4 to 5 days at maximum altitude

Further research is needed before the medications listed below can be recommended for routine use in HAPE prevention (adult dosing):

Tadalafil: 10 mg orally every 12 hours; start day of ascent and continue 3 to 5 days at maximum altitude

Sildenafil: 50 mg orally every 8 hours; start day of ascent and continue 3 to 5 days at maximum altitude

Dexamethasone: 8 mg orally every 12 hours; start day of ascent and continue 48 to 72 hours at maximum altitude

Acetazolamide: 125 to 250 mg orally every 12 hours; start day before ascent and continue 48 to 72 hours at maximum altitude

Treatment§

Nifedipine

Adults and children ≥50 kg: 30 mg extended-release orally every 12 hours

Amlodipine¥

Children 6 to 17 years old and ≥25 kg: 2.5 to 5 mg orally once daily

Children 1 to 5 years old or <25 kg: 0.1 to 0.6 mg/kg/dose orally once daily (maximum 5 mg/day); oral liquid available

Duration (both agents): Continue until descent completed, symptoms resolved, and SpO2 normal for altitude

Further research is needed before the medications listed below can be recommended for routine use in HAPE treatment (adult dosing):

Tadalafil: 10 mg orally every 12 hours

Sildenafil: 50 mg orally every 8 hours

Duration: Continue until descent completed, symptoms resolved, and SpO2 normal for altitude

AMS: acute mountain sickness; HACE: high-altitude cerebral edema; HAPE: high-altitude pulmonary edema; IM: intramuscularly; IV: intravenously; NSAID: nonsteroidal antiinflammatory drug; HAI: high-altitude illness; SpO2: oxygen saturation.

* Gradual ascent is the best strategy for prevention of HAI. Early recognition of symptoms and prompt treatment are critical to reduce risk of progression to serious HAI (such as HAPE and HACE). Reserve pharmacologic prophylaxis for patients who have a history of HAPE or recurrent AMS and patients at high risk (as well as selected patients at moderate risk) of developing AMS/HACE according to criteria listed in the separate UpToDate content. Refer to UpToDate content on unique pediatric considerations for discussion on prevention in children. Provision of these medications for "rescue" treatment is also reasonable.

¶ For immediate administration in children, a liquid acetazolamide solution can be made by crushing a 125 mg or 250 mg tablet and suspending it in cherry, chocolate, or other flavored syrup to hide the bitter taste. A flavored oral suspension useful in patients who cannot swallow pills or for measurement of doses used in smaller children (eg <125 mg) can also be compounded by a pharmacy. Detail is available in the acetazolamide pediatric drug monograph.

Δ May not require pharmacologic treatment. Rest, halt ascent, and symptomatic treatment (eg, acetaminophen or NSAID for headache and ondansetron for nausea/vomiting) may be sufficient. Refer to accompanying UpToDate text.

◊ Treatment with dexamethasone alleviates symptoms of AMS/HACE but does not improve acclimatization. Dexamethasone is not a substitute for immediate descent in HACE.

§ May not require any pharmacologic intervention. In proper setting, rest and supplemental oxygen may be sufficient. Refer to accompanying UpToDate text.

¥ In children, descent and/or supplemental oxygen are preferred treatment and often effective without pharmacologic therapy. Compared with nifedipine, amlodipine offers advantages for small children because of once daily dosing and availability as liquid or appropriately sized tablets, but it has not been studied specifically in children for HAPE treatment. Dosing is based on pediatric pulmonary hypertension management guidelines and expert opinion.
Courtesy of Scott Gallagher, MD and Peter Hackett, MD, with additional data from:
  1. Luks AM, Auerbach PS, Freer L, et al. Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2019 Update. Wilderness Environ Med 2019; 30:S3.
  2. Pollard A, Niermeyer S, Barry P, et al. Children at high altitude: an international consensus statement by an ad hoc committee of the International Society for Mountain Medicine, March 12, 2001. High Alt Med Biol 2001; 2:389.
  3. Abman SH, Hansmann G, Archer SL, et al. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation 2015; 132:2037.
Graphic 76719 Version 17.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟